NCT03357861

Cancer Patients Treated With Immunotherapy in Intensive Care Unit

Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: University Hospital, Grenoble · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.

Detailed description

The place of checkpoint inhibitors (anti-PD-1 and PD-L-1) is currently validated in the management of melanoma and metastatic non-small cell lung cancer. The toxicity profile is specific with adverse effects related to immunity. Some side effects (myocarditis, colitis, interstitial lung disease, etc.) can be severe and patient could be hospitalized in intensive care unit. The question of immunotherapy's imputability in the acute disease is becoming more frequent.

Conditions

• Cancer
• Critical Illness
• Immunotherapy

Timeline

• Start date: 2018-09-01
• Primary completion: 2021-08-23
• Completion: 2021-08-23
• First posted: 2017-11-30
• Last updated: 2021-10-26

Locations

2 sites across 2 countries: Belgium, France